RxDoctor Payments Data

Su Min Cho, MD

Gastroenterology · Pittsburgh, PANPI 1477747509

Payments from drug & device makers

$1,473in general payments, 2019–2025

Across 48 payments — averaging $30.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$572
  • AbbVie$403
  • Pfizer$161
  • E.r. Squibb & Sons, L.L.C.$110
  • Takeda Pharmaceuticals U.S.A., Inc.$89
  • Redhill Biopharma Inc.$39
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$1,44398%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,473 in reported general payments places this provider in the 40th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$58,691
Medicare patients
288
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$568,758
LinzessLinaclotide20$19,378
Mesalamine12$10,095
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg155$3,727
Pantoprazole Sodium199$2,996
Mesalamine ErMesalamine12$2,610
Balsalazide Disodium12$1,636
Omeprazole90$1,605
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates18$1,152
Famotidine76$1,017
CholestyramineCholestyramine (With Sugar)17$724
Sucralfate17$679
Esomeprazole Magnesium22$593
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine16$513
Ondansetron Hcl16$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$572$568,75821 claims
AbbVieLinzess$403$19,37820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →